



The Analysis of Common Drugs of Abuse in an Oral Fluid Matrix using A New Q TRAP[®] Platform

QTRAP® 4500 LC/MS/MS System

Jesse C. Seegmiller, Michael Shaw, Xiaohong Chen and Hua-fen Liu AB SCIEX, Foster City, USA

Abstract

The multiplexing analysis of several compound classes, such as common prescription drugs along with drugs of abuse is very important. The measurement of these drugs has generally been performed using urine as the sample matrix. However, many research laboratories are finding the need to analyze these compounds in oral fluid matrices. This type of testing requires monitoring compounds using a simple sample preparation protocol allowing for the analysis to be performed in a timely fashion, while at the same time providing excellent data quality where the accuracy and precision are uncompromised. In the present study a fast, robust, and reliable method was developed for the detection of 15 compounds in an oral fluid matrix. The LC-MS/MS methods were performed using Multiple Reaction Monitoring (MRM) along with fast positive negative switching detecting all compounds with Limits of Quantitation (LOQ) in-line with the current recommended cutoffs. Throughput was also considered by using the MPX[™]-2 high throughput HPLC system where an increase in sample throughput of 142% was observed. In addition to the above the quantitative positive negative switching capabilities were assessed and it was found to work excellent on the QTRAP® 4500 system.

Introduction

Much interest has surrounded the detection of several pain medications in oral fluid matrices. What makes oral fluid an attractive matrix is the fact that it involves a non-invasive collection. The collection of such a matrix typically involves a collection swab that retains the oral fluid matrix. Once collection has been completed, the drugs are then removed from the swab using an extraction and preservation buffer.

Using LC-MS/MS, we have developed a simple dilute and shoot method to simultaneously quantify these compounds in an oral fluid matrix which is suitable for high volume analysis. The compounds analyzed in this method consisted of 9 drugs





including: Morphine, 6-MAM, Amphetamine, Benzoylecgonine, Codeine, MDA, MDMA, Methamphetamine and PCP.

In addition to the above compounds monitored in positive mode a separate quantitative method was created using positive/negative switching which incorporated the following barbituates that were monitored in negative mode: Amobarbital, Butalbital, Butabarbital, Phenobarbital, Pentabarbital, Secobarbital.

Materials and Methods

Calibrator Preparation:

An oral fluid matrix was spiked with the above drugs at various levels. The calibration curve extended above and below the cutoff and confirmation levels.

Sample Preparation:

The collection workflow was simulated by diluting the oral fluid matrix with an extraction buffer at the appropriate dilution factor. The samples were further diluted in an equal volume of a methanol:water diluent containing 0.1% formic acid.

HPLC Conditions:

Liquid chromatography was performed using the MPXTM-2 high throughput multiplexed HPLC system to achieve maximum throughput. Utilization of the MPXTM-2 system afforded analysis times of less than 5 minutes per sample. The column employed was a Phenomenex Kinetex C18 2.6u 50 x 3.0mm one where 10mM Ammonium Formate in H2O was used in mobile phase A and 0.1% formic acid in methanol in mobile phase B. The injection volume was 10µL. A gradient was applied during chromatographic run and the total run time (not multiplexed) per stream was 6 minutes. The acquisition window was set to 3.5 minutes per stream providing an increase in sample throughput of 142% during multiplexed analysis.

MS/MS Conditions:

All samples were then analyzed using a QTRAP® 4500 instrument operating in electrospray ionization mode and utilizing MRM acquisition. In addition to the above a quantitative positive negative switching method was found to also be viable.

Results

Figure 2 shows the separation of all 15 drug analytes using the positive and negative MRM switching method. In Figure 5 quantitative results are shown for Amphetamine for positive mode only. Figure 6, on the other hand illustrates that the quantitative capabilities are not compromised when using the fast positive negative switching capabilities of the QTRAP® 4500 allowing the monitoring of both positively and negatively charged compounds in the same experiment.





Figure 3. The fast Positive Negative switching capabilities of the AB SCIEX QTRAP® 4500TM LC/MS/MS were explored in MRM mode only are displayed.

 IM Acquisition Method IM Ass Spec 5.999 min Im Provide 5.999 min<th>Experiment: 1</th><th></th><th>Scheduled MRM</th><th>Imp</th><th>iort List</th><th></th>	Experiment: 1		Scheduled MRM	Imp	iort List	
	Scarrype. Mnm (Mnm)		Q1 Mass (Da)	Q3 Mass (Da)	Time (msec)	ID
		1	328.100	165.100	5.0	6-MAM_1
	Polarity	2	328.100	211.100	5.0	6-MAM_2
	Positive	3	136.100	91.000	5.0	Amphetamine_1
	O Negative	4	136.100	119.000	5.0	Amphetamine_2
		5	290.100	168.100	5.0	Benzoylecgonir
		6	290.100	105.000	5.0	Benzoylecgonir
		7	300.200	152.100	5.0	Codeine_1
		8	300.200	115.100	5.0	Codeine_2
		9	180.100	105.000	5.0	MDA_1
		10	180.100	133.000	5.0	MDA_2
		<	1404 400	1469 000	16.0)
	Total Scan Time 0.2530 (sec)			Period Summary		
	Edit Parameters	Durat	tion: 5.998	(min) Delay	Time: 0	(sec)
		Cycle	es: 882 🛟	Cycle:	0.4080	(sec)





Figure 5. Quantitative example of Amphetamine in an oral fluid matrice while using MRM and in positive mode only.



Figure 6. Quantitative example of Amphetamine in an oral fluid matrix while switching between positive and negative MRM mode.



ULOQ Compound Name LOQ (ng/mL) (ng/mL) 6-MAM 0.16 20 7.8125 1000 Amphetamine Benzoylecgonine 2.3438 300 Codeine 1.5625 200 MDA 3.9062 500 Compounds MDEA 3.9062 250 monitored in MDMA 3.9062 500 positive mode Methamphetamine 7.8125 1000 Morphine 1.5625 200 Compounds PCP 0.3906 50 monitored in negative mode Amobarbital 31.3 4000 4000 Butalbital 31.3 **Butabarbital** 31.3 4000 Phenobarbital 31.3 4000 Pentabarbital 31.3 4000 Secobarbital 4000 31.3

Table 1 Limits of quantitation attained in this effort.

*Note that the lower sensitivity level for the barbituates was not assessed below 31.3 ng/mL

Figure 7. Quantitative example of Amobarbital (negative mode) in an oral fluid matrix while switching between positive and negative MRM mode.



Conclusions

A simple and robust method, for the detection of 16 drugs in an oral fluid matrix was developed on the AB SCIEX QTRAP® 4500 LC/MS/MS system. This method utilized a simple protein precipitation procedure followed by a dilution step to analyze all of the analytes. When performing quantitation from the positive and negative switching mode, the linearity and precision observed were excellent in comparison to performing positive mode only.

This contribution solidifies the quantitative capabilities of the AB SCIEX QTRAP® 4500 LC/MS/MS system where the fast electronics allow for quantitation in both positive and negative mode without compromising data quality.

For Research Use Only. Not for use in diagnostic procedures.

© 2012 AB SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEXTM is being used under license.

Publication number: 6680112-01, Document number: RUO-MKT-02-0162-A



Headquarters 500 Old Connecticut Path | Framingham, MA 01701 USA Phone 508-383-7700 www.absciex.com International Sales For our office locations please call the division headquarters or refer to our website at www.absciex.com/offices